2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2022
Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definition
2021
Implementation of a volunteer contact tracing program for COVID-19 in the United States: A qualitative focus group study
Shelby T, Hennein R, Schenck C, Clark K, Meyer AJ, Goodwin J, Weeks B, Bond M, Niccolai L, Davis JL, Grau LE. Implementation of a volunteer contact tracing program for COVID-19 in the United States: A qualitative focus group study. PLOS ONE 2021, 16: e0251033. PMID: 33951107, PMCID: PMC8099418, DOI: 10.1371/journal.pone.0251033.Peer-Reviewed Original Research
2020
Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso
Somé FA, Bazié T, Ehrlich HY, Goodwin J, Lehane A, Neya C, Zachari K, Wade M, Ouattara JM, Foy BD, Dabiré RK, Parikh S, Ouédraogo JB. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malaria Journal 2020, 19: 238. PMID: 32631416, PMCID: PMC7339464, DOI: 10.1186/s12936-020-03311-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDay 7 concentrationsSMC administrationMalaria chemopreventionMalaria infectionDay 7 plasma concentrationsHigh malaria transmission seasonBlood spotsFirst monthPfcrt 76TPrevalence of microscopicSubmicroscopic malaria infectionMalaria transmission seasonPlasmodium falciparum infectionPfcrt K76THigh transmission settingsSequential cross-sectional surveysCross-sectional surveyNon-significant trendAmodiaquine metabolismPfmdr1 N86Malaria parasitaemiaFalciparum infectionK76TPlasma concentrations
2019
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh MH, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M, Gerold H, Nowak C, Do H, Mazambani S, Knighton JK, Cha M, Goodwin J, Kang MK, Jeong JY, Lee SY, Faubert B, Xuan Z, Abel ED, Scafoglio C, Shackelford DB, Minna JD, Singh PK, Shulaev V, Bleris L, Hoyt K, Kim J, Inoue M, DeBerardinis RJ, Kim TH, Kim JW. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports 2019, 28: 1860-1878.e9. PMID: 31412252, PMCID: PMC7048935, DOI: 10.1016/j.celrep.2019.07.027.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsApoptosisCarcinoma, Squamous CellCell ProliferationFemaleGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1HumansMaleMembrane ProteinsMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesSignal TransductionSOXB1 Transcription FactorsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsSquamous cell carcinomaCell carcinomaInsufficient therapeutic optionsBlood insulin levelsRenal glucose reabsorptionBlood glucose concentrationTumor growth inhibitionAnti-oxidative capacityMultiple anatomical sitesPI3K/AktGlucose restrictionSCC patientsWorse survivalKetogenic dietInsulin levelsTherapeutic optionsCancer mortalityGlucose reabsorptionSCC tumorsBlood glucoseSCC cellsAnatomical sitesCancer typesMetabolic vulnerabilitiesOxidative stress
2018
Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
Do SK, Jeong JY, Lee SY, Choi JE, Hong MJ, Kang HG, Lee WK, Seok Y, Lee EB, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Neugent ML, Goodwin J, Kim JW, Park JY. Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer. Annals Of Surgical Oncology 2018, 25: 3396-3403. PMID: 30062472, DOI: 10.1245/s10434-018-6677-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerPrognosis of patientsCell lung cancerSingle nucleotide polymorphismsLung cancerStage non-small cell lung cancerSurvival of patientsSquamous cell carcinomaGlucose transporter 1 (GLUT1) geneBetter OSCurative surgerySurgical resectionWorse OSTumor histologyCell carcinomaStratified analysisBackgroundThis studyPatientsMultivariate analysisTransporter 1 geneConclusionsThis studyGene variantsPrognosisBad genotypes
2017
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications 2017, 8: 15503. PMID: 28548087, PMCID: PMC5458561, DOI: 10.1038/ncomms15503.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAnimalsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell Line, TumorCohort StudiesDeoxyglucoseFemaleFluorodeoxyglucose F18Gene Expression ProfilingGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1GlycolysisHumansHydroxybenzoatesLungLung NeoplasmsMaleMiceMice, NudeMiddle AgedPhenotypePositron-Emission TomographyPrognosisSurvival AnalysisUp-RegulationXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerSquamous cell carcinomaLung SqCCCell carcinomaNSCLC subtypesGlycolytic inhibitionLung squamous cell carcinomaCell lung cancerPatient-derived xenograftsNSCLC tumor samplesNSCLC cell linesCancer Genome AtlasClinical presentationPoor prognosisTherapeutic optionsLung cancerPredominant subtypeDistinct metabolic phenotypesSelective vulnerabilityLung adenocarcinomaMurine modelTherapeutic strategiesSqCCTumor samplesMetabolic signatures